Integrated Treatment Program for Hypochondriasis in Primary Care Settings (NCT00368212) | Clinical Trial Compass
CompletedPhase 3
Integrated Treatment Program for Hypochondriasis in Primary Care Settings
United States91 participantsStarted 2005-05
Plain-language summary
This study will evaluate the effectiveness of an integrated three-part treatment program in improving the quality of care and treatment outcomes of people with hypochondriasis in primary care settings.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Has received primary medical care at Harvard Vanguard Medical Associates (HVMA) for at least 12 months prior to study entry
* Expects to continue receiving care from the current primary care physician for at least the next 12 months
* Meets requirement for average hypochondriasis screening score
* Able to speak and read English
* Falls within the top 20% of utilizers of health care services in the HVMA system over the past year
* Has attended no more than one visit to any specialist over the year prior to study entry
Exclusion Criteria:
* Psychiatric illness (e.g., psychosis, dementia, suicidal ideation)
* Somatoform pain disorder or currently receiving treatment for somatoform pain disorder (e.g., relaxation training)
* History of alcohol or substance abuse or dependence within the 12 months prior to study entry
* Terminal medical illness or major medical illness expected to worsen significantly over the next year
* Ongoing symptom-contingent litigation against HVMA
* Monetary compensation for medical disability
What they're measuring
1
Whitely Index
Timeframe: Measured immediately post-treatment and at Months 6 and 12 post-treatment